Professor Raphael Mechoulam, also referred to as the “father of cannabis research,” revealed his newest discovery, cannabidiolic acid methyl ester (EPM301), just a few months in the past. The introduction of this new, patented compound (artificial, absolutely secure acid-based cannabinoid molecules) brought on a wave of pleasure round the way forward for medicinal hashish.
The compound in query was offered to the world in partnership with EPM, a world biotechnology firm primarily based within the U.S. that goals to bridge the hole between the hashish and pharmaceutical industries.
During a current, unique dialog, CEO Reshef Swisa and Dr. Mechoulam, shared the historical past of the journey behind this revolutionary course of and its significance in evolving the usage of CBD as a pharmaceutical drug.
“EPM developed a method to work with the original substances of cannabis,” the Professor defined. “So, whereas all people is discussing THC and CBD, these cannabinoids are literally a secondary substance; they solely seem later within the plant.
“Originally there is an acid that appears in the plant, and those acids are these mysterious worlds of compounds that are much more potent than cannabinoids,” he added.
See additionally: University Of Toronto, Canadian Biotech Company Collaborate On Cannabinoid-Based COVID-19 Treatment
However, these cannabidiolic acids had been unstable, and due to this fact ineffective in pharmaceutical drug growth. Until now, that’s.
Mechoulam’s current revelation stems from the event of a technique that permits to change the acids in a approach that retains them secure sufficient to permit for his or her larg- scale use. This opens the door for additional pharmaceutical experiments, the professor defined.
“We took a cannabidiol acid and we stabilized it by a simple chemical procedure, called esterification; then the compound is stable,” Swisa defined.
The crew then “started looking at the activities of this compound…and found that this particular compound causes suppression of anxiety and suppression of nausea,” he continued, including that this might make an enormous distinction in most cancers sufferers on chemotherapy, in addition to sufferers with IBD (Inflammatory Bowel Disease) or Psoriasis.
Innovating At 88
That CBD and THC may also help with an extended listing of circumstances from irritation and nervousness, to despair and nausea, has been identified for fairly a while now.
See additionally: UNM Study: Cannabis Is Effective In Treating Depression, Improving Mental Health
In reality, Mechoulam was probably probably the most important tutorial to make clear the lively ideas of the hashish plant again within the 1960s, when his work on the Weizmann Institute led to the invention of the human endo-cannabinoid system, crowning him the “father of cannabis research.”
But the 88 year-old researcher’s latest discovery presents cannabidiolic acid as a much more potent compound than CBD or THC — with no identified damaging uncomfortable side effects.
“We badly need new drugs in several diseases and some of the drugs that are available, may be pretty good but they ultimately cause side effects,” he stated, referencing most non-natural pharma medication, wich are semi-synthetic at greatest.
“We have two groups of compounds today that need to have a replacement: these are steroids and opioids. We believe that cannabis carries the ability to introduce replacements to these families.”
An Alternative To Steroids And Opioids
While CBD has been thought-about a substitute for addictive pharmaceuticals for a number of years now, EPM’s patent on the usage of cannabidiolic acid is the primary to show that these medication can primarily be substituted with out main modifications of their effectivity.
“We compare our compound not only to cannabinoids, but to the existing drugs that are applied today,” Mechoulam defined. “So, for example, in IBD we compared our compounds to two conventional products: one is the prednisone (the steroids) and one is a biological drug. And in both of them, we managed to prove that the activity of our compound is very similar to the common one.”
The researcher is optimistic in terms of the long run.
“I sincerely hope that one day we will have, within the next few years, a cannabidiolic acid derivative on the market in parallel to CBD itself.”
See additionally: The Tosh Family: Torn By Injustice, United By Love (And Cannabis)
But he additionally warned of the significance of classifying and regulating medication accurately for his or her medical use, as a way to keep away from undesirable uncomfortable side effects.
“Companies should be careful when they’re taking compounds and claiming therapeutics. They need to do it in accordance with the regulation in order to create consistency in the language…because people confuse recreational use with the medicinal use and aren’t necessarily looking to a specific indication, with specific dosing,” he ended.